-+ 0.00%
-+ 0.00%
-+ 0.00%

BMO Capital Maintains Outperform on Disc Medicine, Lowers Price Target to $100

Benzinga·02/17/2026 14:33:12
Listen to the news
BMO Capital analyst Evan David Seigerman maintains Disc Medicine (NASDAQ:IRON) with a Outperform and lowers the price target from $120 to $100.